# Kurma Partners

> Kurma Partners is a VC fund in Paris backing Health Care and Biotechnology. See 142 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 142
- Last investment: May 2026
- Lead investor: 47%
- Last fund: Oct 2024
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/3107240/
- X (Twitter): https://twitter.com/KurmaPartners
- Website: http://www.kurmapartners.com

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

## Contacts

5 contacts available for Kurma Partners. Shizune tracks 14 team members at Kurma Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kurma-life-science-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.7M–$14M |
| Series A | $3.8M–$98M |
| Series B | $12M–$72M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 41 | 29% |
| Biotechnology | 39 | 27% |
| Medical | 18 | 13% |
| Pharmaceutical | 18 | 13% |
| Therapeutics | 14 | 10% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 31 | 22% |
| Seed | 26 | 18% |
| Series B | 22 | 15% |
| Funding Round | 15 | 11% |
| Series C | 9 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 35 | 25% |
| Switzerland | 6 | 4% |
| Spain | 4 | 3% |
| The Netherlands | 4 | 3% |
| Belgium | 3 | 2% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alain Horvais | Partner | 3 | https://shizune.co/investors/profile/alain-horvais |
| Amanda Gett Chaperot | Partner | 1 | https://shizune.co/investors/profile/amanda-gett |
| Amine Marouf | Principal | 2 | https://shizune.co/investors/profile/amine-marouf |
| Peter Neubeck | Partner | 10 | https://shizune.co/investors/profile/peter-neubeck |
| Philippe Peltier | Partner | 17 | https://shizune.co/investors/profile/philippe-peltier |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nuclidium | NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M | Series B | May 28, 2026 |  |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M | Seed | Apr 29, 2026 |  |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M | Seed | Mar 23, 2026 |  |
| MedinCell | MedinCell is an injectable slow-release drug specialist company. | $55.7M | Post-IPO Equity | Mar 05, 2026 |  |
| Alveus Therapeutics | Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M | Series A | Jan 08, 2026 |  |
| Laigo Bio | Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M | Seed | Dec 03, 2025 |  |
| DAMAE Medical | Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis. | $17.4M | Series B | Nov 11, 2025 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M |  | Sep 25, 2025 |  |

10 of 142 investments shown.

## Co-investors
- [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners) — VC Fund, 44 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 28 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 28 deals together
- [Eurazeo](https://shizune.co/investors/profile/eurazeo-com) — VC Fund, 21 deals together
- [BNP Paribas Développement](https://shizune.co/investors/profile/bnp-paribas-developpement) — VC Fund, 16 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 15 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Health Care Investors in Europe](https://shizune.co/investors/health-care-investors-europe)
- [Health Care VC Funds in Europe](https://shizune.co/investors/health-care-vc-funds-europe)
- [All Investors in France](https://shizune.co/investors/investors-france)
- [All VC Funds in France](https://shizune.co/investors/vc-funds-france)

## FAQ

### What does Kurma Partners invest in?

Kurma Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 142 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Kurma Partners's check size?

Kurma Partners typically joins rounds of $2.7M–$14M at Seed, $3.8M–$98M at Series A and $12M–$72M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kurma Partners participates in.

### How do I contact Kurma Partners?

Public channels for Kurma Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kurma Partners?

The team at Kurma Partners includes Alain Horvais (Partner), Amanda Gett Chaperot (Partner) and Amine Marouf (Principal), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co